Trial intelligence / Profile preview

REGOSTA regorafenib maintenance in bone sarcomas

2024-514637-37-00Phase 3Suspended

Sponsor: Centre Léon Bérard
Start: Aug 2024
Modality: Small Molecules
Countries: 1

Overview

Phase 3, randomised, double-blind trial in bone cancer, osteosarcoma (OS), Ewing sarcoma and 4 more comparing Regorafenib maintenance with Placebo maintenance (2 arms). Primary endpoint: 36-month relapse-free survival rate. Started Aug 2024; status: suspended.

Drugs

regorafenib

Conditions

bone cancerosteosarcoma (OS)Ewing sarcomachondrosarcomaMalignant Fibrous Histiocytoma of Bone (MFH)

Beyond the preview

Go deeper on 2024-514637-37-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514637-37-00.